Management of Male Breast Cancer Should Include More Mastectomy, Less Radiation

Share this article:
More Mastectomy, Less Radiation in Male Breast CA Management
More Mastectomy, Less Radiation in Male Breast CA Management

(HealthDay News) -- Surgical management of male breast cancer (MBC) is considerably different from that of female breast cancer (FBC), according to a study published in the Nov. 15 issue of the International Journal of Radiation Oncology • Biology • Physics.

Emma C. Fields, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues utilized data from the Surveillance, Epidemiology, and End Results database to identify all primary invasive breast cancer, male or female, diagnosed from 1973 to 2008.

The researchers found that there were 4,276 cases of MBC (0.6 percent of all cases) and 718,587 cases of FBC. Mastectomy was used in 87.4 percent of MBC cases versus 38.3 percent of FBC, and breast-conserving surgery was used in 12.6 and 52.6 percent, respectively (P < 10−4). For males with localized breast cancer, there was no significant difference in cause-specific survival (CSS) for the 4.6 percent treated with lumpectomy/radiation therapy (RT) versus the 70 percent treated with mastectomy alone (hazard ratio, 1.33; P = 0.57). For men with regional cancer, post-mastectomy RT was delivered in 33 percent of cases and was not associated with an improvement in CSS (hazard ratio, 1.11; P = 0.37). Use of post-mastectomy RT in MBC increased significantly over time. CSS for MBC improved over time, with the largest significant change for men diagnosed in 1998 to 2008 versus 1973 to 1987.

"Surgical management of MBC is dramatically different than for FBC," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

High-Fat Diet Ups Risk for Certain Breast Cancers

High-Fat Diet Ups Risk for Certain Breast Cancers

High intake of saturated fats is associated with increased risk of certain subtypes of breast cancer.

Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Pfizer announced results from the Phase 2 PALOMA-1 study that is investigating the use of palbociclib (PD-0332991) in combination with letrozole in patients with advanced breast cancer.

Minorities Hit Harder By Breast Cancer Costs

Minorities Hit Harder By Breast Cancer Costs

Racial and ethnic minority patients seem to be more vulnerable to breast cancer-related privations and financial decline.